Organogenesis Holdings March 2017 Investor Presentation

Biopharmaceutical company presentation outlining strategic plans to triple 2015 revenues to $560M by 2020 and achieve $1.00 adjusted earnings through therapeutic and regenerative biologics development. Details a unique opportunity to launch products under dual 361 and BLA regulations, highlighting 86% gross margins and strong balance sheet with long-term 20%+ revenue growth targets.